Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer.

Oncoscience

Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, Yale School of Medicine, New Haven, CT, USA.

Published: September 2020

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640901PMC
http://dx.doi.org/10.18632/oncoscience.514DOI Listing

Publication Analysis

Top Keywords

sacituzumab govitecan
4
govitecan promising
4
promising antibody-drug
4
antibody-drug conjugate
4
conjugate treatment
4
treatment differentiated
4
differentiated endometrial
4
endometrial cancer
4
sacituzumab
1
promising
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!